‘Soliris,’ a PNH treatment, applied by ‘Refund RSA’ next month

The only PNH(paroxysmal nocturnal hemoglobinuria) treatment, ‘Soliris,’ will be applied by RSA from October.

According to the industry concerned on the 18^th, Soliris(eculizumab), which will face the ending of its refund demo project in the coming 30^th, was confirmed to change to the RSA(Risk Sharing Agreement) system by assessment and agreement of the HIRA’s Drug Benefit Deliberation Committee...